<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="595">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04440891</url>
  </required_header>
  <id_info>
    <org_study_id>1904522298</org_study_id>
    <nct_id>NCT04440891</nct_id>
  </id_info>
  <brief_title>Application of TMS Coupled With VR for Slowing the Rate of Cognitive Decline in Patients With Alzheimer's Disease</brief_title>
  <acronym>TMS_AD</acronym>
  <official_title>Application of Transcranial Magnetic Stimulation Coupled With Virtual Reality for Slowing the Rate of Cognitive Decline in Patients With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ali Rezai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West Virginia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized sham control study to evaluate how repetitive Transcranial Magnetic&#xD;
      Stimulation (rTMS), interactive cognitive training, or the combination of rTMS and cognitive&#xD;
      training reduce the cognitive decline of patients diagnosed with Alzheimer's disease&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants may be assigned to one of four experimental arms (1-TMS-Stimulation with X-Torp&#xD;
      task, 2-TMS-Stimulation with MindMotion Go, 3-TMS-Sham with X-Torp task, 4-TMS-Sham with&#xD;
      MindMotion Go.) The study will be conducted in two phases. During Phase 1, participants will&#xD;
      be randomized between experimental conditions 1 and 4. Data will be analyzed upon completion&#xD;
      of Phase1 and Phase 2 will commence only if there is efficacy in the TMS arm. During Phase2,&#xD;
      participants will be randomized to arms 2 and 3.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty with recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">October 3, 2019</start_date>
  <completion_date type="Actual">November 2, 2021</completion_date>
  <primary_completion_date type="Actual">November 2, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive Performance</measure>
    <time_frame>6 months after completion study procedure</time_frame>
    <description>Change in cognitive task performance over time using the total score on the Mini Mental State Examination (range 0-30)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brain MRI</measure>
    <time_frame>6 months after completion of study procedure compared to screening</time_frame>
    <description>Change in brain structure and function over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Memory Performance</measure>
    <time_frame>6 months after completion of study procedure compared to screening</time_frame>
    <description>Total recall on the California Verbal Learning Test - short form (range 0-36)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>TMS-Stimulation with X-Torp task</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMS with VR 1 experimental arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMS-Stimulation with MindMotion Go</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMS with VR 2 experimental arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMS-Sham with X-Torp task</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>TMS sham control with VR 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMS-Sham with MindMotion Go</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>TMS sham control with sham VR 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TMS stimulation with X-Torp task</intervention_name>
    <description>TMS-Stimulation with X-Torp task</description>
    <arm_group_label>TMS-Stimulation with X-Torp task</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TMS-Stimulation with MindMotion Go</intervention_name>
    <description>TMS-Stimulation with MindMotion Go</description>
    <arm_group_label>TMS-Stimulation with MindMotion Go</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TMS-Sham with X-Torp task</intervention_name>
    <description>TMS-Sham with X-Torp task</description>
    <arm_group_label>TMS-Sham with X-Torp task</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TMS-Sham with MindMotion Go</intervention_name>
    <description>TMS-Sham with MindMotion Go</description>
    <arm_group_label>TMS-Sham with MindMotion Go</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Male or Female between 50-85 years of age&#xD;
&#xD;
          -  Able and willing to give informed consent&#xD;
&#xD;
          -  Probable AD consistent with NIA/AA criteria&#xD;
&#xD;
          -  Modified Hachinski Ischemia Scale (MHIS) score of &lt;= 4&#xD;
&#xD;
          -  Geriatric Depression Scale (GDS) score of &lt;= 6&#xD;
&#xD;
          -  Mini Mental State Exam (MMSE) score 18-26. The MMSE adjusted scoring instructions may&#xD;
             be followed for screening patients as applicable.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstable medical conditions&#xD;
&#xD;
          -  Visual impairments&#xD;
&#xD;
          -  Mobility limitations&#xD;
&#xD;
          -  Cognition-enhancing medication unless on a stable dosage for at least 3 months before&#xD;
             the start of the trial.&#xD;
&#xD;
          -  History of epilepsy or seizure disorder&#xD;
&#xD;
          -  History of psychosis&#xD;
&#xD;
          -  Current thoughts of suicidal ideation or self-harm as assessed by the Columbia-Suicide&#xD;
             severity rating scale score&#xD;
&#xD;
          -  Progressive neurological disorder or focal signs of abnormality on neurological exam&#xD;
             as conducted by a neurologist (other than current diagnosis of AD)&#xD;
&#xD;
          -  Tinnitus&#xD;
&#xD;
          -  Metal implants (excluding dental fillings)&#xD;
&#xD;
          -  Possible pregnancy&#xD;
&#xD;
          -  Substance use disorder within the past six months&#xD;
&#xD;
          -  Have other mental or physical conditions that are inappropriate for study&#xD;
             participation at PI's or delegated sub investigator's discretion.&#xD;
&#xD;
          -  Intake of one or a combination of the drugs that may due to their significant seizure&#xD;
             threshold lowering potential&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Haut, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Rockefeller Neuroscience Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Victor Finomore, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Rockefeller Neuroscience Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West Virginia University Rockefeller Neuroscience Institute</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2022</verification_date>
  <study_first_submitted>May 22, 2020</study_first_submitted>
  <study_first_submitted_qc>June 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2020</study_first_posted>
  <last_update_submitted>July 19, 2022</last_update_submitted>
  <last_update_submitted_qc>July 19, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>West Virginia University</investigator_affiliation>
    <investigator_full_name>Ali Rezai</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

